News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Medivation, Inc. (MDVN) Announces First Quarter 2012 Financial Results Teleconference on May 8, 2012



5/2/2012 8:19:18 AM

SAN FRANCISCO, CA--(Marketwire - May 01, 2012) - Medivation, Inc. (NASDAQ: MDVN) today announced that it will host a live teleconference with management to discuss first quarter 2012 financial results and provide a general business update on Tuesday, May 8, 2012 at 4:30 p.m. Eastern Time. A press release for the first quarter of 2012 will be released after markets close on May 8, 2012.

Interested parties may call 877-303-2523 from the U.S. or +1-253-237-1755 internationally.

About Medivation
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partner Astellas, Medivation currently has the investigational drug MDV3100 in Phase 3 development to treat advanced prostate cancer. For more information, please visit us at www.medivation.com.


Contacts:
Patrick Machado
Chief Business & Financial Officer
(415) 829-4101

Anne Bowdidge
Sr. Director, Investor Relations
(650) 218-6900


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES